NCT00993096 - Investigation of the Response Relationship of NN5401 in Type 1 Diabetics | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions

DiabetesDiabetes Mellitus, Type 1

Interventions

DRUG

insulin degludec/insulin aspart

Single dose of 0.4 U/kg body weight injected subcutaneously (under the skin)

DRUG

insulin degludec/insulin aspart

Single dose of 0.6 U/kg body weight injected subcutaneously (under the skin)

DRUG

insulin degludec/insulin aspart

Single dose of 0.8 U/kg body weight injected subcutaneously (under the skin)

DRUG

biphasic insulin aspart 30

Single dose of 0.4 U/kg body weight injected subcutaneously (under the skin)

DRUG

biphasic insulin aspart 30

Single dose of 0.6 U/kg body weight injected subcutaneously (under the skin)

DRUG

biphasic insulin aspart 30

Single dose of 0.8 U/kg body weight injected subcutaneously (under the skin)

Trial Locations (1)

Novo Nordisk Investigational Site, Neuss